NCT00937027

Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis

A Randomized Phase 1 Study Comparing The Safety and Oral Pharmacokinetics Of 0.25 mg and 1.0 mg Aminopterin Tablets In Human Subjects With Psoriasis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Syntrix Biosystems, Inc. · Industry
• Sex: All
• Age: 21 Years – 59 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the safety and pharmacokinetic properties (the absorption, distribution and excretion) of two preparations of aminopterin (0.25 mg tablets and 1.0 mg tablets) following oral administration by subjects with moderate to severe psoriasis.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Aminopterin	oral tablets, 1.0 mg dose, once weekly, two weeks

Timeline

• Start date: 2009-06-01
• Primary completion: 2010-04-01
• Completion: 2010-04-01
• First posted: 2009-07-10
• Last updated: 2019-09-20

Locations

1 site across 1 country: United States